 |
Smoke, then Fire: Lung Cancer Screening Studies Under Further Scrutiny Bruce A. Chabner (p. 348) |
|
Trastuzumab plus Paclitaxel or Docetaxel in HER-2–Negative/HER-2 ECD–Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer Alexandros Ardavanis, Panteleimon Kountourakis, Flora Kyriakou et al. (p. 361) |
|
Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2–Negative Breast Cancer? Francisco J. Esteva (p. 370) |
|
Irinotecan and Other Chemotherapy in Elderly Patients with Colorectal Cancer Claus-Henning Köhne, Gunnar Folprecht, Richard M. Goldberg et al. (p. 390) |
|
Systemic Therapy for Biliary Tract Cancers Aram F. Hezel, Andrew X. Zhu (p. 415) |
|
Commentary: Lung Cancer Screening—Progress or Peril James L. Mulshine (p. 435) |
|
Commentary: CT Screening for Lung Cancer—Caveat Emptor James R. Jett, David E. Midthun (p. 439) |
|
Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy Robert C. Kane, W. David McGuinn, Jr., Ramzi Dagher et al. (p. 445) |
|
The Oncologist Online is grateful for the support of:
|
